Format

Send to

Choose Destination
J Rheumatol. 2016 Jun;43(6):1107-13. doi: 10.3899/jrheum.151067. Epub 2016 Apr 1.

Pulmonary Involvement in the Antisynthetase Syndrome: A Comparative Cross-sectional Study.

Author information

1
From the Institute of Clinical Medicine, and Department of Rheumatology, and Department of Radiology, and Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway.H. Andersson, MD, Institute of Clinical Medicine, and Department of Rheumatology, Oslo University Hospital; T.M. Aaløkken, MD, PhD, Department of Radiology, Oslo University Hospital; A. Günther, MD, Department of Radiology, Oslo University Hospital; G.K. Mynarek, MD, Department of Radiology, Oslo University Hospital; T. Garen, MSc, Department of Rheumatology, Oslo University Hospital; M.B. Lund, MD, PhD, Department of Respiratory Medicine, Oslo University Hospital; Ø. Molberg, Professor, Institute of Clinical Medicine, and Department of Rheumatology, Oslo University Hospital. helena.andersson@medisin.uio.no.
2
From the Institute of Clinical Medicine, and Department of Rheumatology, and Department of Radiology, and Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway.H. Andersson, MD, Institute of Clinical Medicine, and Department of Rheumatology, Oslo University Hospital; T.M. Aaløkken, MD, PhD, Department of Radiology, Oslo University Hospital; A. Günther, MD, Department of Radiology, Oslo University Hospital; G.K. Mynarek, MD, Department of Radiology, Oslo University Hospital; T. Garen, MSc, Department of Rheumatology, Oslo University Hospital; M.B. Lund, MD, PhD, Department of Respiratory Medicine, Oslo University Hospital; Ø. Molberg, Professor, Institute of Clinical Medicine, and Department of Rheumatology, Oslo University Hospital.

Abstract

OBJECTIVE:

Interstitial lung disease (ILD) is a major component of the antisynthetase syndrome, but quantitative data on longterm pulmonary outcome in antisynthetase syndrome are limited. In this study, the main aims were to compare pulmonary function tests (PFT) and the 6-min walking distance (6MWD) between patients with antisynthetase syndrome and healthy sex- and age-matched controls, to evaluate the extent of ILD by lung high-resolution computed tomography (HRCT), and to assess correlations between PFT measures and ILD extent.

METHODS:

Concurrent PFT and 6MWD were performed in 68 patients with antisynthetase syndrome and their individually matched controls. Additionally, in the patients, the extent of ILD was determined in 10 HRCT sections, expressed as percentage of total lung volumes.

RESULTS:

Median disease duration in the antisynthetase syndrome cohort was 71 months. Compared with the matched controls, the patients with antisynthetase syndrome had mean 28%, 27%, and 53% lower absolute values of forced vital capacity (FVC), forced expiratory volume in 1 s, and DLCO (p < 0.001). Mean difference in 6MWD between patients and controls was 116 m (p < 0.001). Median extent of ILD by HRCT was 20% (range 0-73) and correlated with FVC and DLCO. Pulmonary outcome did not differ between Jo1 and non-Jo1 subsets.

CONCLUSION:

To our knowledge, this study is the first to demonstrate a highly significant difference in PFT between patients with antisynthetase syndrome with 6 years of followup and healthy controls. DLCO displayed the highest difference with mean 53% lower value in the patients. FVC and DLCO correlated significantly with ILD extent, indicating these variables as appropriate outcome measures in antisynthetase syndrome-associated ILD.

KEYWORDS:

ANTISYNTHETASE ANTIBODY; ANTISYNTHETASE SYNDROME; INTERSTITIAL LUNG DISEASE; MYOSITIS; PULMONARY FUNCTION TEST

PMID:
27036381
DOI:
10.3899/jrheum.151067
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center